Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up.

Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P.

Otolaryngol Head Neck Surg. 2019 Jul 9:194599819860808. doi: 10.1177/0194599819860808. [Epub ahead of print]

PMID:
31286827
2.

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment.

Carbone A, Gloghini A, Pruneri G, Dolcetti R.

Cancer Med. 2019 Jun;8(6):3012-3016. doi: 10.1002/cam4.2168. Epub 2019 May 8. Review.

3.

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis.

Cron MA, Maillard S, Truffault F, Gualeni AV, Gloghini A, Fadel E, Guihaire J, Behin A, Berrih-Aknin S, Le Panse R.

Front Immunol. 2019 Mar 29;10:539. doi: 10.3389/fimmu.2019.00539. eCollection 2019.

4.

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A.

Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14.

PMID:
30846365
5.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L.

Sci Rep. 2019 Mar 5;9(1):3545. doi: 10.1038/s41598-019-40310-5.

6.

Checkpoint blockade therapy resistance in Hodgkin's lymphoma.

Carbone A, Gloghini A.

Lancet. 2018 Oct 6;392(10154):1194-1196. doi: 10.1016/S0140-6736(18)31867-1. No abstract available.

PMID:
30319105
7.

Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.

Caccuri F, Muraro E, Gloghini A, Turriziani O, Riminucci M, Giagulli C, Mastorci K, Fae' DA, Fiorentini S, Caruso A, Carbone A, Dolcetti R.

Hematol Oncol. 2019 Apr;37(2):176-184. doi: 10.1002/hon.2562. Epub 2018 Nov 6.

PMID:
30261551
8.

Epstein Barr Virus-Associated Hodgkin Lymphoma.

Carbone A, Gloghini A.

Cancers (Basel). 2018 May 25;10(6). pii: E163. doi: 10.3390/cancers10060163.

9.

Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?

Carbone A, Gloghini A, Carlo-Stella C.

Blood. 2018 Jul 5;132(1):17-22. doi: 10.1182/blood-2018-02-833806. Epub 2018 May 1. Review.

10.

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.

Necchi A, Lo Vullo S, Raggi D, Gloghini A, Giannatempo P, Colecchia M, Mariani L.

Eur Urol Focus. 2018 Mar 7. pii: S2405-4569(18)30075-0. doi: 10.1016/j.euf.2018.02.013. [Epub ahead of print]

PMID:
29525380
11.

Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients.

Volpi CC, Gualeni AV, Pietrantonio F, Vaccher E, Carbone A, Gloghini A.

Expert Rev Mol Diagn. 2018 Mar;18(3):259-277. doi: 10.1080/14737159.2018.1440210. Epub 2018 Feb 21. Review.

PMID:
29431533
12.

Current and potential use of pathological targets in the treatment of Hodgkin lymphoma.

Carbone A, Gloghini A.

Am J Hematol. 2018 May;93(5):E117-E120. doi: 10.1002/ajh.25054. Epub 2018 Feb 14. No abstract available.

13.

Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.

Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, De Cecco L, Rizzetti MG, Zanframundo A, Aiello A, Carcangiu ML, Gloghini A, Ferrero S, Licitra L, Greco A, Fugazzola L, Locati LD, Borrello MG.

Endocr Relat Cancer. 2018 Mar;25(3):217-231. doi: 10.1530/ERC-17-0389. Epub 2018 Jan 3.

PMID:
29298817
14.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

15.

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production.

Mogavero A, Maiorana MV, Zanutto S, Varinelli L, Bozzi F, Belfiore A, Volpi CC, Gloghini A, Pierotti MA, Gariboldi M.

Sci Rep. 2017 Nov 22;7(1):15992. doi: 10.1038/s41598-017-16149-z.

16.

How immunologic and genetic biomarkers impact Hodgkin lymphoma classification, diagnosis, and management: a huge potential that yet needs to be exploited.

Carbone A, Gloghini A.

Int J Biol Markers. 2018 May;33(2):137-140. doi: 10.5301/ijbm.5000312. Epub 2017 Oct 28.

PMID:
29099538
17.

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.

Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F.

Ann Oncol. 2017 Dec 1;28(12):3009-3014. doi: 10.1093/annonc/mdx546.

PMID:
29045518
18.

In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating.

Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, Locati L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A.

Hum Pathol. 2018 Apr;74:32-42. doi: 10.1016/j.humpath.2017.09.011. Epub 2017 Oct 6.

PMID:
28993274
19.

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.

Necchi A, Lo Vullo S, Perrone F, Raggi D, Giannatempo P, Calareso G, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Togliardi E, Colecchia M, Busico A, Gloghini A, Testi A, Mariani L, Salvioni R.

BJU Int. 2018 Mar;121(3):348-356. doi: 10.1111/bju.14013. Epub 2017 Oct 4.

20.

Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research.

Necchi A, Raggi D, Volpi CC, Giannatempo P, Colecchia M, Gloghini A.

Eur Urol Focus. 2019 Jul;5(4):689-692. doi: 10.1016/j.euf.2017.08.002. Epub 2017 Aug 30.

PMID:
28855072
21.

Teaching Digital Pathology: The International School of Digital Pathology and Proposed Syllabus.

Mea VD, Carbone A, Di Loreto C, Bueno G, De Paoli P, García-Rojo M, de Mena D, Gloghini A, Ilyas M, Laurinavicius A, Rasmusson A, Milione M, Dolcetti R, Pagani M, Stoppini A, Sulfaro S, Bartolo M, Mazzon E, Soyer HP, Pantanowitz L.

J Pathol Inform. 2017 Jul 25;8:27. doi: 10.4103/jpi.jpi_17_17. eCollection 2017.

22.

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F.

Br J Cancer. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27.

23.

Hodgkin lymphoma classification: Are we at a crossroads?

Carbone A, Gloghini A.

Cancer. 2017 Oct 1;123(19):3654-3655. doi: 10.1002/cncr.30824. Epub 2017 Jun 16. No abstract available.

24.

Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.

Alfieri S, Iacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, Bossi P.

Oncotarget. 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822.

25.

Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.

Gloghini A, Volpi CC, Gualeni AV, Dolcetti R, Bongarzone I, De Paoli P, Carbone A.

Expert Rev Hematol. 2017 Jun;10(6):505-514. doi: 10.1080/17474086.2017.1326815. Epub 2017 May 16. Review.

PMID:
28468596
26.

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs).

Negri T, Brich S, Bozzi F, Volpi CV, Gualeni AV, Stacchiotti S, De Cecco L, Canevari S, Gloghini A, Pilotti S.

Oncotarget. 2017 May 16;8(20):32492-32504. doi: 10.18632/oncotarget.16477.

27.

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C, Volpi CC, Beznoussenko GV, Milione M, Leoni V, Gloghini A, Mironov AA, Leo E, Pilotti S, Pierotti MA, Bongarzone I, Gariboldi M.

J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.

28.

microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.

Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, Maurichi A, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M.

Genes (Basel). 2016 Dec 14;7(12). pii: E124.

29.

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F.

Clin Cancer Res. 2017 May 15;23(10):2414-2422. doi: 10.1158/1078-0432.CCR-16-1863. Epub 2016 Oct 25.

30.

The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.

Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R.

Int J Cancer. 2017 Mar 15;140(6):1233-1245. doi: 10.1002/ijc.30473. Epub 2016 Oct 27. Review.

31.

Epstein-Barr virus associated lymphomas in people with HIV.

Carbone A, Volpi CC, Gualeni AV, Gloghini A.

Curr Opin HIV AIDS. 2017 Jan;12(1):39-46. Review.

PMID:
27755151
32.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

33.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

34.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

35.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F.

Cancer Discov. 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297. Epub 2016 Jun 20.

36.

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.

Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A, Stacchiotti S, Pierotti MA, Pilotti S, Negri T.

Oncotarget. 2016 Jul 19;7(29):45015-45026. doi: 10.18632/oncotarget.7523.

37.

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F.

J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.

38.

E1 detection as prognosticator in human papillomavirus-positive head and neck cancers.

Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.

Int J Biol Markers. 2016 Apr-Jun;31(2):0. doi: 10.5301/jbm.5000193. Epub 2016 Mar 22.

PMID:
27040135
39.

A lymphomagenic role for HIV beyond immune suppression?

Dolcetti R, Gloghini A, Caruso A, Carbone A.

Blood. 2016 Mar 17;127(11):1403-9. doi: 10.1182/blood-2015-11-681411. Epub 2016 Jan 14. Review.

40.

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.

Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M.

Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599.

41.

Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients.

Ciniselli CM, Volpi CC, Cortelazzi B, Gualeni AV, Bottelli S, Perrone F, Pilotti S, Gloghini A, Verderio P.

Hum Pathol. 2016 Jan;47(1):157-8. doi: 10.1016/j.humpath.2015.06.026. Epub 2015 Oct 3. No abstract available.

PMID:
26527520
42.

4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.

Varinelli L, Caccia D, Volpi CC, Caccia C, De Bortoli M, Taverna E, Gualeni AV, Leoni V, Gloghini A, Manenti G, Bongarzone I.

Endocr Relat Cancer. 2015 Oct;22(5):759-75. doi: 10.1530/ERC-15-0299. Epub 2015 Jul 23.

PMID:
26206776
43.

Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.

Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C.

J Pathol. 2015 Sep;237(1):4-13. doi: 10.1002/path.4558. Epub 2015 Jun 3. Review.

PMID:
25953622
44.

A novel semi-automated in situ hybridisation protocol for microRNA detection in paraffin embedded tissue sections.

Gualeni AV, Volpi CC, Carbone A, Gloghini A.

J Clin Pathol. 2015 Aug;68(8):661-4. doi: 10.1136/jclinpath-2015-203005. Epub 2015 Apr 30.

PMID:
25934842
45.

Cell-secreted signals shape lymphoma identity.

Gloghini A, Bongarzone I.

Semin Cancer Biol. 2015 Oct;34:81-91. doi: 10.1016/j.semcancer.2015.02.001. Epub 2015 Mar 30. Review.

PMID:
25837156
46.

Primary central nervous system lymphoma.

Gloghini A, Carbone A.

J Neurosci Rural Pract. 2015 Jan;6(1):2-3. doi: 10.4103/0976-3147.143162. No abstract available.

47.

Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.

Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, Bossi P, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, Licitra L, Pilotti S, Perrone F.

J Oral Pathol Med. 2015 Oct;44(9):734-45. doi: 10.1111/jop.12301. Epub 2014 Dec 14.

PMID:
25495427
48.

Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.

Gloghini A, Bosco A, Ponzoni M, Spina M, Carbone A.

Expert Rev Hematol. 2015 Apr;8(2):217-23. doi: 10.1586/17474086.2015.991388. Epub 2014 Dec 9. Review.

PMID:
25487651
49.

Follicular dendritic cell pattern in early lymphomas involving follicles.

Carbone A, Gloghini A.

Adv Anat Pathol. 2014 Jul;21(4):260-9. doi: 10.1097/PAP.0000000000000030. Review.

PMID:
24911251
50.

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.

Carbone A, Gloghini A, Kwong YL, Younes A.

Ann Hematol. 2014 Aug;93(8):1263-77. doi: 10.1007/s00277-014-2116-y. Epub 2014 May 29. Review.

Supplemental Content

Loading ...
Support Center